<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05625100</url>
  </required_header>
  <id_info>
    <org_study_id>7885</org_study_id>
    <nct_id>NCT05625100</nct_id>
  </id_info>
  <brief_title>Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis</brief_title>
  <acronym>CXCL13-LYME</acronym>
  <official_title>Place of Intrathecal CXCL-13 in the Diagnosis of Lyme Neuroborreliosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroborreliosis (NBL) is diagnosed in 10-15% of patients with Lyme borreliosis. In Europe in&#xD;
      adults, the main clinical manifestation is called &quot;Bannwarth syndrome&quot;. This includes painful&#xD;
      meningoradiculitis, sometimes accompanied by cranial nerve neuritis. Current European&#xD;
      guidelines issued by the European Federation of Neurological Societies (EFNS) recommend the&#xD;
      following triad for the diagnosis of &quot;definite NBL&quot;: (i) Neurological symptoms suggestive of&#xD;
      NBL without any other obvious cause; (ii) CSF pleocytosis; (iii) Intrathecal production of&#xD;
      specific anti-Borreliella antibodies. CXCL13, C-X-C chemokine motif ligand 13, is a chemokine&#xD;
      implicated in B cell chemotaxis. Extensive literature exists on the analysis of CXCL13i as a&#xD;
      diagnostic marker for acute NBL. A recent meta-analysis from 2018, published by Rupprecht et&#xD;
      al finds an overall sensitivity and specificity of 89% and 96% respectively, indicating&#xD;
      satisfactory diagnostic value. In this study, the investigators wish to assess the place of&#xD;
      this new marker in the diagnosis of neuroborreliosis before proposing it as a test carried&#xD;
      out by the Borrelia CNR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positivity of the marker (CXCL13-intrathecal) for known cases of NBL and negativity of this one for known non-NBL cases</measure>
    <time_frame>Files analysed retrospectively from January 01, 2013 to December 31, 2018 will be examined</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Lyme Borreliosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major subject (≥18 years old) subject having consulted at the HUS between 01/01/2013 and&#xD;
        31/12/2018&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major subject (≥18 years old)&#xD;
&#xD;
          -  Subject having consulted at the HUS between 01/01/2013 and 31/12/2018&#xD;
&#xD;
          -  Subject not having, after being informed, expressed their opposition to the reuse of&#xD;
             their data for the purposes of this research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject who expressed their opposition to participating in the study&#xD;
&#xD;
          -  Subject under guardianship or curatorship&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Benoit JAULHAC, MD, PhD</last_name>
    <phone>33 3 69 55 14 52</phone>
    <email>benoit.jaulhac@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service Laboratoire de Bactériologie - Plateau Technique de Microbiologie - CHU de Strasbourg - France</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoit JAULHAC, MD, PhD</last_name>
      <phone>33 3 69 55 14 52</phone>
      <email>benoit.jaulhac@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Benoit JAULHAC, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine GRILLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure Dolfus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lyme borreliosis</keyword>
  <keyword>Lyme neuroborreliosis</keyword>
  <keyword>Bannwarth syndrome</keyword>
  <keyword>Intrathecal CXCL-13</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Borrelia Infections</mesh_term>
    <mesh_term>Lyme Disease</mesh_term>
    <mesh_term>Lyme Neuroborreliosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

